comms@paragonbiosci.com

62 items

January 12, 2023

Evozyne Creates AI Model with NVIDIA for Novel Protein Design, Expected to Accelerate Drug Development
– New AI model, co-developed by Evozyne [...]
January 11, 2023

Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics
– Study data shows investigational new drug, [...]
January 11, 2023

Veteran Technology Executive Mike Gamson Named Evozyne CEO
– Gamson to set commercial direction, strengthen [...]
November 3, 2022

Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
– Clinical stage biopharmaceutical company completes upsized, [...]
June 24, 2022

Outstanding First Half for Paragon and its Portfolio Companies
Paragon and its portfolio companies continue to [...]
May 25, 2022

Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
– Funding expected to provide sufficient capital [...]
April 5, 2022

Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies
Expansion builds on initial strategic collaboration and [...]
March 1, 2022

Emalex Biosciences Expands CNS Platform to Advance Treatment for Restless Legs Syndrome with Augmentation
License agreement secures potential research of ecopipam [...]

Previous 234 Next